Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study

被引：0

作者：

Zeidan, Amer M. ^{[1
]}

Hu, Xin ^{[2
]}

Long, Jessica B. ^{[2
]}

Wang, Rong ^{[2
]}

Huntington, Scott F. ^{[1
]}

Podoltsev, Nikolai A. ^{[1
]}

Gore, Steven ^{[1
]}

Ma, Xiaomei ^{[2
]}

Davidoff, Amy J. ^{[2
]}

机构：

[1] Yale Univ Sch Med, New Haven, CT USA

[2] Yale Univ Sch Publ Hlth, New Haven, CT USA

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.394.394

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

394

引用

页数：5

共 50 条

[1] Hypomethylating Agent Therapy Use and Survival in Older Patients With Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study
Zeidan, Amer M.
Hu, Xin
Long, Jessica B.
Wang, Rong
Ma, Xiaomei
Podoltsev, Nikolai A.
Huntington, Scott F.
Gore, Steven D.
Davidoff, Amy J.
[J]. CANCER, 2017, 123 (19) : 3754 - 3762
[2] HYPOMETHYLATING AGENT THERAPY USE AND SURVIVAL IN OLDER PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA IN USA: A LARGE POPULATION-BASED STUDY
Zeidan, A.
Hu, X.
Long, J. B.
Wang, R.
Ma, X.
Podoltsev, N.
Huntington, S.
Gore, S. D.
Davidoff, A. J.
[J]. LEUKEMIA RESEARCH, 2017, 55 : S20 - S21
[3] HYPOMETHYLATING AGENT THERAPY USE AND SURVIVAL IN OLDER PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROMES IN USA: A LARGE POPULATION-BASED STUDY
Zeidan, A.
Hu, X.
Long, J. B.
Wang, R.
Huntington, S. F.
Podoltsev, N.
Giri, S.
Stahl, M.
Gore, S.
Ma, X.
Davidoff, A. J.
[J]. LEUKEMIA RESEARCH, 2017, 55 : S75 - S76
[4] Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study.
Zeidan, Amer M.
Hu, Xin
Long, Jessica B.
Wang, Rong
Huntington, Scott F.
Podoltsev, Nikolai Alexandrovich
Giri, Smith
Stahl, Maximilian
Gore, Steven
Ma, Xiaomei
Davidoff, Amy J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[5] Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Zeidan, Amer M.
Wang, Rong
Wang, Xiaoyi
Shallis, Rory M.
Podoltsev, Nikolai A.
Bewersdorf, Jan P.
Huntington, Scott F.
Neparidze, Natalia
Giri, Smith
Gore, Steven D.
Davidoff, Amy J.
Ma, Xiaomei
[J]. BLOOD ADVANCES, 2020, 4 (10) : 2192 - 2201
[6] A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015
Ruan, Gordon
Smith, Caleb J.
Day, Courtney
Harmsen, William
Mangaonkar, Abhishek A.
Alkhateeb, Hassan B.
Begna, Kebede H.
Al-Kali, Aref
Litzow, Mark
Hogan, William J.
Gangat, Naseema
Pardanani, Animesh
Elliott, Michelle A.
Tefferi, Ayalew
Go, Ronald S.
Patnaik, Mrinal M.
Shah, Mithun Vinod
[J]. BLOOD, 2020, 136
[7] Long-Term Survival of Older Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agent Therapy: A Large Population-Based Analysis
Stahl, Maximilian
Hu, Xin
Wang, Rong
Ma, Xiaomei
Huntington, Scott
Podoltsev, Nikolai A.
Gore, Steven D.
Abel, Gregory A.
Davidoff, Amy J.
Zeidan, Amer M.
[J]. BLOOD, 2017, 130
[8] Hypomethylating Agent Therapy for Chronic Myelomonocytic Leukemia Does Not Impact Acute Myeloid Leukemia Transformation or Survival
Niyongere, Sandrine
Kathari, Yamini
Singh, Zeba
Vannorsdall, Emily J.
Emadi, Ashkan
Vu Doung
Baer, Maria R.
[J]. BLOOD, 2020, 136
[9] Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States
Zeidan, Amer M.
Wang, Rong
Wang, Xiaoyi
Shallis, Rory M.
Podoltsev, Nikolai A.
Bewersdorf, Jan Philipp
Huntington, Scott F.
Neparidze, Natalia
Giri, Smith
Gore, Steven D.
Davidoff, Amy J.
Ma, Xiaomei
[J]. BLOOD, 2019, 134
[10] Temporal trend in survival for chronic myelomonocytic leukemia in the US: a population-based study
Lesegretain, Arnaud
Brunner, Andrew
Benzohra, Aziz
Fathi, Amir T.
[J]. LEUKEMIA & LYMPHOMA, 2023, 64 (13) : 2156 - 2164

← 1 2 3 4 5 →